The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Dose-escalation results from the BELLWAVE-010 study of nemtabrutinib plus venetoclax in R/R CLL
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses the results from the dose-escalation portion of the BELLWAVE-010 study (NCT05947851), which is evaluating the combination of the third-generation BTK inhibitor nemtabrutinib and venetoclax in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Ghia highlights that the results are encouraging reassuring results, with no unexpected toxicity and high response rates at both doses evaluated. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
